Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports
Joseph A. Manfredi
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Search for more papers by this authorRivers P. Wall
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Search for more papers by this authorDavid C. Sane
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Search for more papers by this authorCorresponding Author
Gregory A. Braden MD
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157Search for more papers by this authorJoseph A. Manfredi
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Search for more papers by this authorRivers P. Wall
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Search for more papers by this authorDavid C. Sane
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Search for more papers by this authorCorresponding Author
Gregory A. Braden MD
Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157Search for more papers by this authorAbstract
Heparin-induced thrombocytopenia (HIT) is a well-documented complication of heparin anticoagulation therapy. Heparin's frequent use in the cardiovascular population poses a significant challenge for managing patients with HIT in need of percutaneous coronary intervention (PCI). We describe four patients with HIT who successfully underwent PCI without thrombotic or hemorrhagic complications while on lepirudin. Cathet Cardiovasc Intervent 2001;52:468–472. © 2001 Wiley-Liss, Inc.
REFERENCES
- 1 Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322–328.
- 2 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535–540.
- 3 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf 1997; 17: 325–341.
- 4 Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Ann Rev Med 1999; 50: 129–147.
- 5 Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Throm Haemost 1992; 68: 95–96.
- 6 Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381–385.
- 7 Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia. Thromb Haemost 1991; 66: 734–736.
- 8 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27–30.
- 9 Warkentin TE, Hayward CP, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371–379.
- 10 Tomer A. A sensitive and a specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haemotol 1997; 98: 648–656.
- 11 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–1335.
- 12 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Throm Haemost 1992: 67: 545–549.
- 13
Hale LP,
Smith K,
Braden GA,
Owen J.
Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
Cathet Cardiovasc Diagn
1998;
45:
318–322.
10.1002/(SICI)1097-0304(199811)45:3<318::AID-CCD23>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 14 Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG. Blood 1996; 88(Suppl 1): 626a.
- 15 Moore JA, Burket MW, Puri S, Temesy-Armos P, Lachant N, Skeel R. Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn 1994; 32: 286–287.
- 16 Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998; 35(Suppl 4): 17–25.
- 17
Lewis BE,
Iaffaldano R,
McKiernan TL,
Rao L,
Donkin J,
Wallenga JM.
Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome.
Cathet Cardiovasc Diagn
1996;
38:
206–209.
10.1002/(SICI)1097-0304(199606)38:2<206::AID-CCD20>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 18 Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Bettina E, Volpel H, Potszsch B, Luz M. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999: 100: 587–593.
- 19 Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Blood 1996; 88(Suppl 1): 281a.
- 20 Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Potzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73–80.
- 21 Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999; 100: 1528–1532.
- 22 Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764–769.
- 23 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095–7101.
- 24 Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992; 10: 211–232.
- 25 Verstraete M, Zoldhelyi P. Novel antithrombotic drug in development. Drugs 1995; 49: 856–884.
- 26 Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559–562.
